Mariya Pavlova1, Anna Starshinova1, Irina
Chernokhaeva1, Ekaterina Belyaeva1 and Nadezhda Sapozhnikova1
Source : http://erj.ersjournals.com/content/48/suppl_60/PA2683
Phthisiopulmonology, St. Petersburg Scientific Research Institute of
Phthisiopulmonology, St. Petersburg, Russian Federation
To determine efficiency of treatment of XDR-TB with the use of therapy
Content and methods:
in St-Petersburg Research Institute of Phthisiopulmonology from 2013 to
2015, 49 patients with XDR lung TB, from 18 to 60 have been treated.
Linezolid was used in 24 patients with XDR-TB during the first 6 months
of intensive phase of treatment in the dose - 600 mg per day
intravenously, by drop infusion in combination with 5-6 anti TB drugs
taking into account range of MBT drug resistance ? Studied
group (group I). Control group -group II(n=25), used 5-6 anti TB drugs
without linezolid.We carried out statistical analysis with the use of
the program Statistica 6.0. We applied the criterion
6 months of therapy symptoms of intoxication were not detected among
all patients both in studied and control groups. Negative results of
bacterial excretion were registered in I group significantly higher
than in II group: 62.5%(14) against 36.0%(9),(p>0.05). Adverse
drug reactions were noted with equal frequency in both groups(29.1%(7)
vs 32.0%(8). In patients who used linezolid hepatotoxic reactions
occurred in 4 of 7 patients, in 3 patients ? leukopenia,
neutropenia, anemia. In control group - hepatotoxic reactions(5 of 8),
diarrhea(3 of 8). When symptomatic therapy was applied adverse drug
reactions were resolved. Intensive phase of treatment in both groups
lasted 8 months.
inclusion of linezolid in combined anti TB therapy resulted in
cessation of bacterial excretion in 6 months in twice more frequent
cases vs therapy without linezolid. Incidence of adverse drug reactions
when linezolid usage was not higher than occurred for standard therapy.
Image : https://www.msfaccess.org/...